| Personalized medicine in diabetes: regulatory considerations. | |
| | |
MedLine Citation:
|
PMID: 20144322 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Personalized medicine has become a topic of great interest because of its potential to improve patient care and optimize therapeutic strategy. The U.S. Food and Drug Administration (FDA) is interested in promoting personalized medicine, whenever appropriate, to protect and promote the public health. The ability to better diagnose, screen, and manage patients with diabetes in order to individualize care should lead to better health outcomes and a large benefit to public health. This article describes FDA regulatory considerations for devices intended for use as personalized medicine tools for the diagnosis and treatment of patients with diabetes. |
| | |
Authors:
|
Courtney C Harper |
Publication Detail:
|
Type: Journal Article Date: 2009-07-01 |
Journal Detail:
|
Title: Journal of diabetes science and technology Volume: 3 ISSN: 1932-2968 ISO Abbreviation: J Diabetes Sci Technol Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2010-02-10 Completed Date: 2010-06-02 Revised Date: 2011-03-11 |
Medline Journal Info:
|
Nlm Unique ID: 101306166 Medline TA: J Diabetes Sci Technol Country: United States |
Other Details:
|
Languages: eng Pagination: 739-42 Citation Subset: IM |
Copyright Information:
|
Copyright 2009 Diabetes Technology Society. |
Affiliation:
|
Office of In Vitro Diagnostic Device Evaluation and Safety, Center for Devices and Radiological Health, US Food and Drug Administration, Rockville, Maryland 20850, USA. courtney.harper@fda.hhs.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Diabetes Mellitus
/
therapy* Humans Individualized Medicine* Public Health / legislation & jurisprudence* United States United States Food and Drug Administration / legislation & jurisprudence* Validation Studies as Topic |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Technologies for diabetes genomics.
Next Document: Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine...